Date: 2017-09-20
Type of information: Nomination
Compound: member of the board of directors
Company: Bluebird bio (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 20, 2017, bluebird bio announced that it has appointed Mary Lynne Hedley, Ph.D. to its Board of Directors. Mary Lynne Hedley, Ph.D., co-founded Tesaro in 2010 and since that time, has served as the company’s President and as a member of its board of directors. Prior to founding Tesaro, Dr. Hedley served as Executive Vice President of Operations and Chief Scientific Officer of Abraxis BioScience. She served as Executive Vice President of Eisai Corporation of North America from January 2008 until July 2009, following the company's acquisition of MGI PHARMA in January 2008. Dr. Hedley served in various positions at MGI PHARMA from 2004 through its acquisition in January 2008, most recently as Executive Vice President and Chief Scientific Officer. Prior to that, Dr. Hedley co-founded and served as the President and Chief Executive Officer of ZYCOS, which was acquired by MGI PHARMA in 2004.
- Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard University and earned her doctoral degree in immunology from the University of Texas, Southwestern Medical Center and her Bachelor of Science degree in microbiology from Purdue University. She serves on the Board of Directors of Millendo Therapeutics Inc. and Youville Place, an assisted living facility. She served on the Board of Directors of Receptos from April 2014 until August 2015, when Receptos was acquired by Celgene.
Financial terms:
Latest news:
Is general: Yes
